Published: July 2023
We analyzed close to 570 contract manufacturing organizations that have the required capabilities to offer oral solid dosage manufacturing services across different scales of operation. Of these, discover the 10 leading contract manufacturing organizations and their capabilities in this industry. These contract manufacturing organizations have been instrumental in meeting the global demand for tablet manufacturing and capsule manufacturing
Despite several novel dosage forms being introduced into the pharmaceutical and nutraceutical sectors, oral solid dosage (OSD), particularly tablets and capsules, continue to be the most popular and widely used dosage forms. The growing demand for complex oral solid formulations, such as extended release or controlled release delivery systems requires specialized production techniques and facility designs. Moreover, rapid scale-up and scale-out of the OSD manufacturing operations is a complex process which requires specialized equipment for manufacturing processes, highly contained work environment, and a team of experts with multidisciplinary knowledge. Additionally, there is a rising demand for capsule manufacturing, driven by the growth of the nutraceutical industry. As a result, drug developers are increasingly relying on contract manufacturers to leverage their capabilities and yield cost savings opportunities. Roots Analysis has conducted an exhaustive study on Oral Solid Dosage Manufacturing Market, featuring the current market landscape and future opportunities for the contract manufacturing organizations involved in the oral solid dosage manufacturing, over a span of 12 years.
The conventional oral solid dose manufacturing is undergoing innovation, driven by the increasing consumer demand for convenient and visually appealing delivery forms, alongside a growing need for compounds with improved solubility and bioavailability. Recent trends include multilayer tablets, softgel capsules, chewable capsules and tablets, micro tablets and smart forms such as chip-in-a-tablet. Their manufacturing requires the use of advanced equipment and materials. As such, the contract manufacturers are supporting the oral solid dosage market by upgrading their capabilities.
Below, we have listed (in alphabetical order), the top 10 contract manufacturing organizations offering oral solid dose manufacturing.
Interested in exploring all 570+ Oral Solid Dose Manufacturing Service Providers? Click here to get Free Insights
This article highlights the 10 leading contract manufacturers to watch out for in this industry. These companies were chosen based on their service portfolio strength. It is essential to note that the selection of the top players can differ substantially according to the defined criteria.
 |
Alcami is a US-based firm offering services to support the formulation development, analytical testing, manufacturing, and packaging of biologics and small molecule therapeutics. As of 2023, the firm has contributed to the launch of over 50 products and filing of more than 500 Investigational New Drug (IND) applications through its manufacturing services. It is interesting to note that, in January 2023, two private investment firms, namely GHO Capital Partners and The Vistria Group completed the acquisition of Alcami, with an aim to further scale the Alcami’s offerings, capacity and geographic reach.
Alcami offers drug development and manufacturing services for the following types of oral solids:
Oral Solid Dosage Manufacturing Facility: North Carolina (US)
Recent Developments: In September 2022, it announced the addition of 12,000 sq. ft. solid-state characterization laboratory in North Carolina, US to complement its existing oral solid drug development, manufacturing, and analytical capabilities. Further information related to services offered, scales of operation, type of primary packaging offered, and regulatory certifications and accreditations is available in the full report.
Additional Service(s) Offered for Oral Solids: Pre-formulation / formulation development, bioavailability enhancement, process development, analytical development, scale-up, packaging and labelling, regulatory support, technology transfer, and packaging, and labeling.
 |
Cambrex is a contract development and manufacturing organization (CDMO) offering custom services for drug substances and drug product lifecycle, ranging from excipient compatibility studies to the scale-up and packaging of finished dosage forms. Further, in August 2019, Cambrex was acquired by Permira, a global private equity firm, to support the growth of the former company’s service portfolio. It is interesting to note that, Cambrex was recognized by the annual CMO (Contract Manufacturing Organization) Leadership Awards in the categories of Quality and Service, for the eighth consecutive year in 2022. In November 2022, the company acquired Snapdragon Chemistry as part of its strategy to boost growth in the active pharmaceutical ingredient (API) batch and continuous flow process development. By harnessing automation technology and equipment, they sought to overcome intricate process and analytical development hurdles efficiently.:
Cambrex offers drug development and manufacturing services for the following types of oral solids:
Oral Solid Dosage Manufacturing Facilities: New Jersey (US) and Quebec (Canada)
Recent Developments: In October 2022, Cambrex expanded its capacity for small molecule development and manufacturing through the construction of a 21,000 sq. ft. research and development facility in Minnesota, US. Further information related to services offered, scales of operation, type of primary packaging offered, and regulatory certifications and accreditations is available in the full report.
Additional Service(s) Offered for Oral Solids: Pre-formulation / formulation development, bioavailability enhancement, process development, analytical development, scale-up, packaging and labelling, regulatory support, technology transfer, and packaging and labeling.
 |
Catalent, a US-based company, is a global service provider for product development, stability testing, manufacturing, packaging, and drug delivery to the pharmaceutical and biopharmaceutical industry. The firm currently operates across four business segments, namely Biologics, Clinical Supply Services, Oral and Specialty Delivery, and Softgel and Oral Technologies. The company’s oral solid dose business segment has proven experience to handle conventional as well as complex oral solid dosage forms, such as orphan and rare disease oral products and potent or controlled substance materials. Some examples of Catalent’s integrated programs for oral solid drugs include OptiForm® Solution Suite, Xpress Pharmaceutics™, Optiform Total Supply and OneXpress® Solution. It is interesting to note that, as of 2023, the company has launched 20 drug products in oral dissolution format, and 50 products in controlled release delivery format.
Catalent offers drug development and manufacturing services for the following types of oral solids:
Oral Solid Dosage Manufacturing Facilities: Kentucky (US), Missouri (US), California (US), New Jersey (US), Florida (US), Nottingham (UK), Swindon (UK), Schorndorf (Germany), Eberbach (Germany), Beinheim (France), Aprilia (Italy), Kakegawa (Japan), Buenos Aires (Argentina), Indaiatuba (Brazil) and Sorocaba (Brazil)
Recent Developments: In August 2022, the company acquired Metrics Contract Services from Mayne Pharma in order to strengthen and expand its oral solid dosage manufacturing, development and packaging capabilities. Further information related to services offered, scales of operation, type of primary packaging offered, and regulatory certifications and accreditations is available in the full report.
Additional Service(s) Offered for Oral Solids: Pre-formulation / formulation development, bioavailability enhancement, taste masking, process development, analytical development, scale-up and technology transfer.
 |
Aenova is a European contract development and manufacturing service provider for nutraceuticals and pharmaceuticals, including prescription and over-the-counter (OTC) drugs. It was established in 2008, by a merger between Swiss Caps, a contract soft capsule manufacturer and Dragenopharm, a contract manufacturer of generic prescription drugs. Further, in August 2012, the company was acquired by BC Partners. As a one-stop-shop service provider, the company’s portfolio of offerings spans the entire lifecycle of the product. The company currently operates through the following three business segments: BU Solids (SOL), BU Semisolids and Liquids (SEL), and BU Softgel Capsules (SGL).
Aenova offers drug development and manufacturing services for the following types of oral solids:
Oral Solid Dosage Manufacturing Facilities: North Carolina (US), Bavaria (Germany), Kerry (Ireland), Hesse (Germany), Westphalia (Germany), Aargau (Switzerland), Muntenia (Romania), Bern (Switzerland) and Lazio (Italy)
Recent Developments: In January 2023, Aenova expanded its capsule filling capacity with the installation of an Industria Macchine Automatiche (IMA) capsule filling machine, IMA Adapta 200 at its Regensburg manufacturing facility in Bavaria, Germany. Further information related to the services offered, scale of operation, type of primary packaging offered, and regulatory certifications and accreditations is available in the full report.
Additional Service(s) Offered for Oral Solids: Pre-formulation / formulation development, bioavailability enhancement, process development, analytical development, scale-up, packaging and labelling, regulatory support, and technology transfer.
 |
Almac is a UK-based CDMO, which offers a broad range of services to support its clients across each step of the drug development lifecycle. These services range from early and late-phase pharmaceutical development, product launch, commercial drug product manufacture, commercial packaging, and serialization through to commercial storage and distribution. Established as Galen in 1968, the business eventually sold its operations in active pharmaceutical ingredient (API) manufacturing and chemical development, clinical trial supply, and clinical technologies to Almac. It is worth highlighting that in February 2023, the company was awarded six CDMO Leadership Awards, across all the core categories, namely excellence in capabilities (small pharma), compatibility (overall and small pharma), expertise (overall and small pharma), quality (overall and small pharma), reliability (overall and small pharma) and service (small pharma).
Almac offers drug development and manufacturing services for the following types of oral solids:
Oral Solid Dosage Manufacturing Facilities: Craigavon (Northern Ireland) and Charnwood (England)
Recent Developments: In December 2022, Almac announced the completion of the first stage of its good manufacturing facilities (GMP) API facility expansion in Northern Ireland, UK. Further information related to services offered, scales of operation, type of primary packaging offered, and regulatory certifications and accreditations is available in the full report.
Additional Service(s) Offered for Oral Solids: Pre-formulation / formulation development, bioavailability enhancement, process development, analytical development, scale-up, packaging and labelling, and regulatory support.
 |
Lonza is one of the most prominent players in the contract development and manufacturing domain. The company started its business by producing calcium carbide using electricity produced from turbines. It has now evolved into a prominent stakeholder in the contract manufacturing domain and is engaged in diverse spheres through multiple functioning segments. Having a diverse portfolio curated for the healthcare industry, the company operates across four main divisions, namely Small Molecules, Biologics, Cell and Gene Therapies, and Capsules & Health Ingredients. Additionally, the company operates across five continents through more than 30 locations.
Lonza offers drug development and manufacturing services for the following types of oral solids:
Oral Solid Dosage Manufacturing Facilities: Oregon (US), Florida (US), Valais (Switzerland), Ticino (Switzerland) and Guangdong (China)
Recent Developments: In November 2022, Lonza announced the launch of its revolutionary oral delivery capsule solution, Capsugel Enprotect for intestinal drug delivery. Further information related to services offered, scales of operation, type of primary packaging offered and regulatory certifications and accreditations is available in the full report.
Additional Service(s) Offered for Oral Solids: Pre-formulation / formulation development, bioavailability enhancement, taste masking, process development, analytical development, scale-up, packaging and labelling, and regulatory support.
 |
Recipharm is focused on offering custom contract development and manufacturing (CDMO) services for drugs and drug delivery devices. It operates across the four business segments, namely Advanced Drug Delivery Systems, Steriles, Solids & Others, and Development and Licensing. Through the utilization of specialized technologies such as modified release, controlled release, and fixed dose combinations, Recipharm has extensive experience in assisting clients throughout all stages of clinical development, including the development of new chemical entities (NCEs) and the enhancement of products with existing drug substances. This experience extends to both clinical development and commercial manufacturing, ensuring comprehensive support throughout the entire pharmaceutical lifecycle. With over 30 facilities spread across 10 countries, Recipharm has established a strong global presence to serve its clients effectively.
Recipharm offers drug development and manufacturing services for the following types of oral solids:
Oral Solid Dosage Manufacturing Facilities: Pessac (France), Zwickau (Germany), Milan (Italy), Lisbon (Portugal), Barcelona (Spain), Madrid (Spain), Scania County (Sweden), Stockholm (Sweden), Södermanland County (Sweden), England (UK) and Karnataka (India)
Recent Developments: In December 2022, Recipharm announced an extension of its commercial manufacturing agreement of RedHill Biopharma’s drug, Talicia® (delayed-release capsule) to 2026. Gregor Kawaletz, Head of Business Unit Oral Solid Dosages at Recipharm, stated, "Our collaboration with RedHill to develop and manufacture Talicia has been ongoing since 2015, and extending it until 2026 signifies a significant milestone in our partnership."
Further information related to services offered, scales of operation, type of primary packaging offered and regulatory certifications and accreditations is available in the full report.
Additional Service(s) Offered for Oral Solids: Pre-formulation / formulation development, analytical development, scale-up, bioavailability enhancement, packaging and labelling, regulatory support, and technology transfer.
 |
With presence in more than 140 countries and 30 years of experience in the pharmaceutical industry, Hetero Drugs is one of the leading manufacturers of key active pharmaceutical ingredients (APIs) and generic formulations, globally. The firm has a vast product portfolio of over 300 APIs and more than 200 finished dosage forms, within therapeutic areas, such as cardiology, metabolic disorders, hepatology, immunology, nephrology, neurology, oncology, ophthalmology, and urology. It is worth mentioning that the company caters to 40% of the current demand for APIs for anti-retroviral (ARV) drugs and finished dosage forms used to treat HIV/AIDS. In addition to services related to APIs, the firm offers biosimilars, branded generics, finished dosage forms, injectables, and custom process development manufacturing services for pharmaceutical companies.
Hetero Drugs offers drug development and manufacturing services for the following types of oral solids:
Oral Solid Dosage Manufacturing Facilities: The company has over 36 manufacturing sites that cater to diversified market demand in China, Egypt, India, Indonesia, Mexico, Russia, Saudi Arabia and US. The formulation facilities of the firm are located in Himachal Pradesh (India) and Telangana (India).
Recent Developments: In October 2022, the company acquired the manufacturing plant of Johnson & Johnson located in Penjerla, spread across 55.27 acres, in Telangana, India, in order to expand its capabilities in manufacturing sterile pharmaceuticals and biologics. Further information related to services offered, scales of operation, type of primary packaging offered and regulatory certifications and accreditations is available in the full report.
Additional Service(s) Offered for Oral Solids: Pre-formulation / formulation development, process development, analytical development, scale-up, packaging and labelling, regulatory support, and technology transfer.
 |
Ind-Swift Laboratories is an evolving contract service provider based in Chandigarh, India. The company claims to have in-house capabilities for API development, finished dosage forms, non-infringing processes, and contract manufacturing. The firm offers services for all the stages of drug development, from molecular research and formulation development, to manufacturing of drug substances and finished dosage forms. The company caters to a diverse range of pharmaceutical clients, through its multiple manufacturing sites situated in various locations across India, along with an independent state-of-the-art research and development center based in Maharashtra, India.
Ind-Swift Laboratories offers drug development and manufacturing services for the following types of oral solids:
Oral Solid Dosage Manufacturing Facilities: Himachal Pradesh (India), Haryana (India), Jammu Kashmir (India), Punjab (India)
Recent Developments: In April 2022, the company attained the ISO 14001:2015 and ISO 45001:2018 certification for its research and development site in Mohali, India and Samba, India. The company aims to establish a profitable, sustainable and system-driven, globally recognized pharmaceutical organization that delivers a vast range of high-quality pharma products to global markets through its strong customer base, intellectual workforce, effective systems and cutting-edge technology. Further information related to services offered, scales of operation, type of primary packaging offered and regulatory certifications and accreditations is available in the full report.
Additional Service(s) Offered for Oral Solids: Pre-formulation / formulation development, bioavailability enhancement, process development, analytical development, scale-up, packaging and labelling, regulatory support, and technology transfer.
 |
Rubicon Research is a pharmaceutical company focused on developing value-added formulations, building a portfolio of generic prescription, and manufacturing over-the-counter drugs across several therapeutic areas. The company’s portfolio includes vast array of product and services including drug device combinations, fixed-dose combinations, injectables, nasal, ophthalmic, oral liquids, oral solids, and topicals. It is worth noting that the company has more than 50 issued patents in drug-delivery technologies sector. In 2021, the drug pipeline of the firm witnessed over 10 approvals and launches across the segments of oral solids and ophthalmic formulations. Further, it has over 130 products in development phase and 22 filed products under the Food and Drug Administration (FDA) assessment.
Rubicon Research offers drug development and manufacturing services for the following types of oral solids:
Oral Solid Dosage Manufacturing Facilities: New Jersey (US), Vaughan (Canada) and Maharashtra (India)
Recent Developments: The company has diversified its development capabilities with emphasis on commercial manufacturing resulting in numerous product approvals and launches. The manufacturing facility based in Ambernath, Maharashtra, India, has global regulatory licenses for commercial manufacturing and supply of oral solid dosage forms. Further information related to services offered, scales of operation, type of primary packaging offered and regulatory certifications and accreditations is available in the full report.
Additional Service(s) Offered for Oral Solids: Pre-formulation / formulation development, bioavailability enhancement, process development, analytical development, scale-up, packaging and labelling, regulatory support, and technology transfer.
The above presentation features ten most promising service providers selected from a pool of over 570 contract manufacturing organizations that we have compiled and researched. If you are interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com
MEDIA CITATIONS
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES
.png)
